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Aminoacyl-tRNA synthetases (ARSs) are ubiquitously expressed enzymes
responsible for charging tRNAs with their cognate amino acids, therefore essen-
tial for the first step in protein synthesis. Although the majority of protein syn-
thesis happens in the cytosol, an additional translation apparatus is required to
translate the 13 mitochondrial DNA-encoded proteins important for oxidative
phosphorylation. Most ARS genes in these cellular compartments are distinct,
but two genes are common, encoding aminoacyl-tRNA synthetases of glycine
(GARS) and lysine (KARS) in both mitochondria and the cytosol. Mutations in
the majority of the 37 nuclear-encoded human ARS genes have been linked to a
variety of recessive and dominant tissue-specific disorders. Current data indi-
cate that impaired enzyme function could explain the pathogenicity, however
not all pathogenic ARSs mutations result in deficient catalytic function; thus,
the consequences of mutations may arise from other molecular mechanisms.
The peripheral nerves are frequently affected, as illustrated by the high number
of mutations in cytosolic and bifunctional tRNA synthetases causing Charcot–
Marie–Tooth disease (CMT). Here we provide insights on the pathomecha-
nisms of CMT-causing tRNA synthetases with specific focus on the two bifunc-
tional tRNA synthetases (GARS, KARS).
Keywords: aminoacyl-tRNA synthetases; cytosolic and mitochondrial
translation; Charcot-Marie-Tooth disease
Aminoacyl-tRNA synthetase proteins (ARS) are a fam-
ily of nuclear-encoded enzymes that ensure correct
translation of the genetic code by conjugating each of
the 20 amino acids to their cognate tRNA molecule [1–
3]. This aminoacylation reaction provides the substrate
for the protein translation process. There are two
groups of ARS enzymes: the cytosolic ARS, which are
responsible for supplying aminoacyl-tRNA conjugates
for general protein translation; mitochondrial ARSs,
which are imported into the mitochondrial matrix and
charge amino acids to their mitochondrial genome-
encoded tRNA molecules (mt-tRNA). For most amino
acids, there are dedicated isoforms encoded in the
genome for each of these compartments, but in the case
of glycyl-ARS (GARS) and lysyl-ARS (KARS), the
proteins are bifunctional and localised to both the cyto-
sol and the mitochondria [4]. Furthermore, no mito-
chondrial glutamyl-tRNA synthetase (QARS) has been
identified; Q-tRNA is instead suggested to be formed
by postconjugation modification of glutamic acid [5].
Mitochondrial tRNA synthetases
(ARS2 genes)
All mt-ARSs are synthesised in the cytosol; addressed
to, and imported into, the mitochondria due to the
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presence of an N-terminal presequence (mitochondrial
targeting sequence), which is cleaved upon entry to the
mitochondria [6]. Pathogenic variants of mt-ARSs show
a variety of phenotypes involving tissues with high
energy demand. Despite their crucial housekeeping
function and ubiquitous expression, mutations in mt-
ARSs have been implicated in a variety of paediatric
and adult onset human neurological disorders of the
brain, spinal cord and motor neurons in addition to
disorders predominantly affecting other tissues mani-
festing as cardiomyopathy, myopathy, sensorineural
hearing loss and endocrine symptoms [1–3,7]. A large
number of autosomal recessive disorders specifically
affect the brain, and result in lesions of certain neuronal
cell types. The most typical clinical presentations are
leukoencephalopathy with brainstem and spinal cord
involvement and high lactate (LBSL) due to DARS2
mutations [8], leukoencephalopathy with thalamus and
brainstem involvement and high lactate (LTBL) caused
by EARS2 mutations [9], but other mt-ARS mutations
may also cause white matter lesions. Mutations within
the AARS2 gene result in two different phenotypes: late
onset ovarian failure and leukodystrophy and infantile
mitochondrial cardiomyopathy [10]. MARS2 mutations
have been previously linked to Autosomal Recessive
Spastic Ataxia with Leukoencephalopathy (ARSAL)
[11], presentations similar to that observed in Alpers–
Huttenlocher syndrome have been reported in patients
with mutations in CARS2 [12], FARS2 [13], PARS2
[14], TARS2 [15], VARS2 [16] NARS2 [16], RARS2 [17]
andWARS2 [18]. These diseases display a broad clinical
spectrum and may be further complicated with other
symptoms such as developmental delay (NARS2,
PARS2), pontocerebellar hypoplasia (RARS2), visual
impairment (FARS2) psychomotor delay (TARS2) and
microcephaly (VARS2). Other ARS2 diseases show
characteristic tissue distribution, isolated sensorineural
hearing loss (MARS2 [19], NARS2 [20]), hearing loss
with premature ovarian failure (Perrault syndrome,
HARS2 [21] and LARS2 [22]), mitochondrial myopathy,
lactic acidosis and sideroblastic anaemia (MLASA syn-
drome (YARS2 [23]), or hyperuricaemia, pulmonary
hypertension renal failure and alkalosis (HUPRA syn-
drome, SARS2 [24]). To date, no ARS2 mutations have
been reported in human disease with an autosomal
dominant mode of inheritance, all mutations are either
homozygous or compound heterozygous (Fig. 1).
Bifunctional and cytosolic tRNA
synthetases
While autosomal dominant pathogenic variants of the
cytosolic ARSs were originally reported in peripheral
neuropathies, newly emerging data show a spectrum of
recessive disorders. Autosomal dominant neuropathies
have been associated with mutations in AARS [25,26],
HARS [27], YARS [28], GARS [29] and WARS [30].
Autosomal recessive ARS mutations have been
recently reported in a range of conditions often affect-
ing the central nervous system (microcephaly AARS,
QARS [31,32]), epileptic encephalopathy (AARS,
QARS [31–34]), sensorineural hearing loss (HARS,
KARS [35,36]), developmental delay (IARS, KARS,
QARS, YARS [34,37–39]), or causing liver dysfunction
(IARS, MARS, YARS [39–41]) and lung disease
(MARS [39,41]). The large variability of the clinical
presentations caused by mutations even in a single
ARS gene is remarkable and needs further investiga-
tions (Fig. 1).
Charcot–Marie–Tooth disease caused
by defects of ARS mutations
Charcot–Marie–Tooth disease (CMT) was the first
human disorder to be linked to ARSs mutations. CMT
is the most common inherited neurological disease in
European populations, with an estimated prevalence of
around 1–4 per 10 000 individuals [42,43], and is char-
acterised by symmetric atrophy and weakness in the dis-
tal muscles associated with sensory impairment caused
by progressive degeneration of the peripheral nerves.
CMT is broadly divided into two forms: demyelinating
(CMT1) primarily affecting the myelin sheaths of
peripheral neurons or axonal form (CMT2) primarily
affecting the axons. These can be differentiated based
on the electrophysiological and pathological presenta-
tion, however intermediate phenotypes exist [44]. Five
of the 20 genes encoding cytosolic ARSs (AARS,
GARS, WARS, YARS and HARS) have been reported
to cause dominant inherited CMT, with the number
expected to increase, and remarkably, no other domi-
nantly inherited disease has been linked with mutations
(Fig. 1). Furthermore, two additional ARS genes have
also been associated with CMT. Heterozygous missense
mutations in MARS have been found in two families
causing CMT2U [45,46] and peripheral neuropathy was
reported in two patients with compound heterozygous
mutations in KARS [38].
Besides the fact that new mutations are continuously
discovered, neither the cause of the selective vulnera-
bility, nor the molecular mechanisms leading to the
disease, are well understood. Currently, there are no
disease modifying therapies for CMT and clinical care
focuses on managing symptoms with physical therapy
and orthopaedic surgery. The similarity of clinical pre-
sentation resulting from dominant inherited ARS
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mutations implies a shared mechanism of disease,
though no mechanism so far has been proven. The
major mechanisms proposed consist of: reduced
aminoacylation activity, altered dimerisation or
localisation, gain-of-function pathogenic interactions
and loss of noncanonical function (Fig. 2). We exam-
ine the evidence supporting, contradicting and lacking
for each mechanism.
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Fig. 1. Clinical variability of diseases caused by ARSs mutations. (A) Tissues commonly affected by mutations in cytosolic, bifunctional and
mitochondrial ARS genes. (B) Common neurological presentations reported in cytosolic, bifunctional and mitochondrial ARS genes, with
peripheral neuropathy highlighted. Solid line indicates dominant mode of inheritance, dashed line indicates recessive mode of inheritance.
References: AARS [33,48,50,96], DARS [97],HARS [27], IARS [37,40] MARS [45,98], RARS [99], SARS [18], WARS [30], ARS [28,39], QARS
[34], GARS [7,29,71], KARS [38], AARS2 [10,67], CARS2 [12], DARS2 [8], EARS2 [9], FARS2[13,100], HARS2 [21], IARS2 [101,102], LARS2
[22], MARS2 [11,19], NARS2 [20,103,104], PARS2 [14,103], RARS2 [17,105], SARS2 [24], TARS2 [15], VARS2 [15,16], WARS2 [18,106],
YARS2 [23,107].
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Evidence of impaired catalytic
function
The central housekeeping role of ARS proteins in cel-
lular physiology implies that defects in their function
would cause cellular dysfunction. Reduction in both
the aminoacylation reaction rate and cognate accuracy
of the enzyme present possible pathogenic mecha-
nisms. ARS proteins act via a two-step process to
facilitate tRNA-amino acid conjugation and the activ-
ity of mutant ARS enzymes can be determined in vitro
using recombinant human protein [47]. These enzy-
matic assays have generally found pathogenic variants
of cytosolic ARS to cause at least some degree of
reduced enzymatic activity, with the notable exception
of the YARS p.Glu196Lys variant (Table 1). Yeast
complementation studies on the translational function
of the mutant ARS and constructs using CMT-asso-
ciated variants have been shown to cause either lethal-
ity or reduced growth in most, but not all, cytosolic
ARS enzymes (Table 1). Although there is strong evi-
dence of impaired catalytic function in CMT-
associated cytosolic ARS variants, the potential mech-
anism is less well characterised; with possibilities
including dysfunction of the catalytic site, abnormal
protein dimer formation and altered localisation.
By mapping ARS mutations onto the 3D protein
structures determined by X-ray crystallography, it is
possible to determine whether they are clustered around
particular functional sites. The p.Asp71Tyr and
p.Gly102Arg AARS mutations are predicted to lie
within the catalytic domain, whereas the common p,
Arg329His mutation is predicted to be at the tRNA-
binding domain and the p.Asp893Asn and p.Glu688Gly
mutations are reported within the editing domain [48–
50]. Moving to YARS and HARS, most reported muta-
tions are predicted to lie on the catalytic domain,
though importantly, unlike AARS, these proteins do
not contain editing domains [28,46,51–53]. Though no
crystal structure has been determined for MARS, com-
putational prediction maps one mutation,
p.Arg6128Cys, between the catalytic and tRNA-binding
domains, and another mutation, p.Pro800Thr, to the
tRNA-binding domain [45,46], while the recently
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Fig. 2. Possible pathological pathways of
axonal degeneration in tRNA synthetase
mutations.
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reported WARS mutation, p.His257Arg, is in the cat-
alytic domain [30]. The diversity of mutations between
the different major domains reported for cytosolic ARS
rules out dysfunction at either the catalytic site or in
tRNA-binding as the sole mode of pathogenicity. Fur-
thermore, the lack of clustering within any domain sug-
gests impairment of canonical domain function may not
be relevant to the disease pathophysiology, with sec-
ondary roles of the affected residues potentially being
important.
Questions remain as to how the reduction in catalytic
capacity in dominant mutations causes peripheral neu-
ropathy specifically, without affecting other tissues with
high demand for protein synthesis. A possibility is that
similar biochemical impairment is seen as in recessive
phenotypes but milder due to the presence of some wild-
type protein and therefore specifically effecting the unu-
sual proteomic demands of peripheral nerves. Alterna-
tively, dimerisation, localisation or more complex
elements specific for peripheral nerves such as neuro-
muscular junction, neuronal receptors (neuropilin 1)
may be involved in conjunction with the catalytic deficit
to cause peripheral nerve-specific presentation. The
question about aminoacylation deficiency and disease
causality is controversial and still open in the literature,
although we think that it may be causative at least in
some mutations. However, other pathological mecha-
nisms may have an additive effect and for certain muta-
tions aminoacylation is not altered and different factors
may explain the disease phenotype.
Table 1. Functional evidence on pathogenicity of CMT-causing tRNA synthetase mutations. CMT, Charcot–Marie–Tooth disease; dHMN,
distal hereditary motor neuropathy; AARS, alanyl-tRNA synthetase; YARS, tyrosine-tRNA synthetase; HARS, histidyl-tRNA synthetase;
MARS, methionyl-tRNA synthetase; WARS, tryptophanyl-tRNA synthetase; GARS, glycyl-tRNA synthetase; KARS, lysyl-tRNA synthetase;
NRP1, Neuropilin-1 precursor; VEGF, Vascular endothelial growth factor; TrkA/B/C, tropomyosin receptor kinase A/B/C.
Experimental method Effect of mutations
Cytosolic tRNA synthetase
AARS Recombinant enzyme activity: Reduced: p.Asn71Tyr [50]; p.Arg329His [50];
Yeast growth: Lethal: p.Asn71Tyr [50]; Gly102Arg [108] p.Arg329His [50]
Mouse: Purkinje cells loss, ataxia, no effect on NMJ morphology: Ala734Glu [109] (mutation in
mouse Aars)
HARS Yeast growth: Lethal: p.Thr132Ile [27]; p.Pro134His [27]; p.Arg137Gln [52]; p.Asp364Tyr [27]
Reduced: p.Asp175Glu [27]
Caenorhabditis elegans: Motor neuron toxicity: p.Arg137Gln (targeted to 4-aminobutyrate neurons) [52]
MARS Yeast growth: Lethal: p.Arg618Cys (mutation has incomplete penetrance) [45]
p.Pro800Thr lacks functional evidence
WARS Recombinant enzyme activity: Abnormal: His257Arg [30]
Yeast growth: Abnormal: Hist257Arg [30]
YARS Recombinant enzyme activity: Reduced: p.Gly41Arg [110]; p.153-156delValLysGlnVal [110]
Conflicting (reduced and normal): p.Glu196Lys [28,110]
Yeast growth: Lethal: p.Gly41Arg [28]
Reduced: p.Glu196Gln [51]; p.Glu196Lys (yeast orthologue, human is normal) [28]
Human N2a neuroblastoma cells: Reduced axonal distribution: p.Gly41Arg [28],
Bifunctional tRNA synthetase
GARS Recombinant enzyme activity: Reduced: p.Ala57Val (minor reduction) [61]; p.Leu129Pro [111]; p.Asp146Asn [61];
p.Ser211Phe [61]; p.Gly240Arg [61]; p.Pro244Leu [61]; p.Ile280Phe [61]; p.His418Arg [61];
p.Gly526Arg [61]; p.Gly598Ala [61]
Normal: p.Glu71Gly [54]; p.Asp500Asn [54]; p.Ser581Leu [54]
Yeast growth: Lethal: p.Pro244Leu; p.His418Arg [111]; p.Gly526Arg [111];
Reduced: p.Leu129Pro [111]; p.Asp146Asn [61]
Normal: p.Glu71Gly [111]; p.Gly240Arg [60,111]; p.Ile280Phe [61]; p.Gly598Ala [60]
Drosophila: Abnormal dendritic morphology, altered mitochondrial translation, and progressive NMJ
degeneration: p.Glu71Gly [89]; p.Gly240Arg [89,112]; p.Gly526Arg [89]; p.Pro234Lys,Tyr [112]
Mouse: Secreted mutant GARS binds to NRP1, interfering with VEGF
NMJ dysfunction, aberrant binding to TrkA, TrkB, and TrkC, receptors in sensory neurons:
p.Pro278Lys [75,76]; p.Cys201Arg [75,76]
KARS Recombinant enzyme activity: Reduced: p.Leu133His [38]
Yeast growth: Lethal: p.Tyr173Serfs*7 [38]
Normal: p.Leu133His [38]
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Dimerisation
All CMT-associated ARS enzymes (AARS, GARS,
WARS, YARS, HARS) catalytically function as dimers,
and disruption to the dimer functionality has been sug-
gested as a mechanism of pathogenicity in ARS-related
CMT. Clustering of mutations of GARS has been
reported around the homodimer interface, and muta-
tions affecting the dimer interface have been shown to
cause subtle conformational alterations to mutant wild-
type dimers [54,55]. In addition, Dewan et al. [56]
demonstrated that due to a H7 helix located in motif 1
of human KARS (member of the multi-synthetase com-
plex), it is also capable of dimerisation. The effects of
mutations on dimerisation have not been reported for
either AARS or WARS, and some YARS mutations
have been found to have no effect on monomer–dimer
equilibrium [57–59]. A role of dimerisation presents sev-
eral mechanistic possibilities, namely that (a) CMT-
associated variants cannot form dimers and are there-
fore inactive, (b) CMT-associated variants form unsta-
ble dimers which are subsequently either aggregated or
degraded or that (c) CMT-associated variants do form
stable dimers which are either deficient in aminoacyla-
tion activity, deficient in other noncanonical functions
or have a toxic gain-of-function.
Addressing the first possibility, several GARS and
YARS variants have been shown to have binding
affinities equivalent to, or exceeding that of, the wild-
type protein [54,57], thus ruling out decreased dimeri-
sation. Concerning dimer stability, structural studies of
CMT-associated YARS variants show both increased
and decreased protein stability, suggesting protein
instability and aggregation per se is not a common
mechanism. Animal studies of mutant and wild-type
YARS and GARS have shown equivalent expression
of the protein in the cell body [54,60,61], and further-
more, specific quantification of the transfected mutant
GARS is equivalent at the cell body to wild-type [54],
showing that the expression level of the protein is
unaffected and therefore degradation is not a factor. It
must therefore be asked: what evidence exists for the
role of stable toxic ARS dimers? In vitro enzymatic
assays have already shown that although aminoacyla-
tion is often affected in mutant homodimers, it is not
a common feature of all CMT-associated mutations
and therefore, considering the dominant mode of
inheritance, it should be examined whether the
aminoacylation activity of tRNA heterodimers may
have a role. A study, looking at CMT-associated
mutations in zebrafish showed that overexpression of
the homologue of the nondimerising p.Thr130Lys
mutation reduced NMJ toxicity of the CMT-associated
p.Gly526Arg mutation when alongside normal expres-
sion of wild-type gars, suggesting that dimerisation of
the mutant protein with the wild-type is necessary for
pathogenicity [62]. Supporting the potential for a
stable dimer engaging in toxic neomorphic binding, a
recent study examined the structural and catalytic
properties of three CMT-associated YARS variants
and showed that, while other properties such as con-
formational alteration of dimer structure were not
common, exposure of an internal site on the dimers
was, and this facilitates increased binding to TRIM28
[57]. How this or other neomorphic-binding partners
are involved in the pathogenesis of remains to be eluci-
dated, but it provides a principle along which variants
in other genes could be examined.
Cellular localisation
Alteration to the cellular distribution of cytosolic
enzymes presents another pathogenic mechanism. If
mutations disrupt the distribution of ARS proteins
within the cell, and cause a deficit of protein activity
in the axons of peripheral neurons, which are often
much longer than axons of the central nervous system,
this may plausibly explain why mutations cause
length-dependent pathology in the long axons. How-
ever, the few studies that have investigated distribution
both in vitro and in vivo have shown mixed results in
alterations resulting from CMT-causing mutations. In
the case of YARS, a clustering of expression can be
observed around neuronal projections, which was
abolished in N2a cells transfected with CMT-causing
YARS mutations (p.Gly45Arg, p.Gln196Lys) [28]. A
HARS mutation, p.Arg137G [52], modelled in
Caenorhabditis elegans has shown a normal pattern of
axonal expression alongside morphological abnormali-
ties and three different YARS variants (p.Gly41Arg,
p.153-156delValLysGlnVal, p.Glu196Lys) modelled in
Drosophila showed no change in axonal localisation.
Also the distribution of the mutant Gars in a CMT2D
mouse model indicated unaltered localisation in the
sciatic nerve fibres [41]. Therefore, despite evidence of
altered localisation in some ARS mutations, it is cur-
rently unknown whether it is a common mechanism of
disease.
Noncanonical functions
The lack of clear mechanistic evidence supporting defi-
cits in aminoacylation (catalytic function) has led the
suggestion that cytosolic ARS disease may relate to
entirely different ‘noncanonical’ ARS functions. This
could include the loss of a noncanonical physiological
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ARS function, or alternatively can be a gain of patho-
logical function. During the evolutionary process,
cytosolic ARS proteins, or complexes formed from
them, have accrued additional functions to their core
‘canonical’ role in aminoacylating tRNA molecules
with roles as diverse as mRNA splicing [63], modula-
tion of angiogenesis [64] as well as roles in injury
repair in the peripheral nervous system [65,66].
Whether disease-associated mutations in cytosolic
ARSs cause disruption to a noncanonical function in
the peripheral nervous system, remains to be con-
firmed, and if any alterations are found it is important
to show that this is replicated across different muta-
tions and critically across the disease-associated genes,
which are not known to share many noncanonical
functions. Investigation of loss of noncanonical func-
tion is further complicated as known functions are
often not present in lower organisms, therefore limit-
ing the relevance of more simple biological models
such as yeast or C. elegans.
Neuromuscular diseases caused by
defects of bifunctional ARS mutations
Reported mutations in bifunctional enzymes, GARS
and KARS show either recessive or dominant inheri-
tance, with strikingly different tissue specific clinical
manifestations. Dominant GARS mutations have been
identified in patients with axonal peripheral neuropathy
(CMT2D or distal spinal muscular atrophy type:
dSMA-V) [29,55] and recessive mutations were reported
with patients with predominant cardiomyopathy leading
to death in an infant or cardiomyopathy and mitochon-
drial myopathy with exercise intolerance [7,67,68].
Mutations in KARS have been so far associated with
various phenotypes: autosomal recessive CMT [38],
nonsyndromic hearing loss [36], childhood-onset visual
impairment with progressive microcephaly with com-
bined mitochondrial respiratory chain defect [68], and a
severe cardiomyopathy associated with myopathy, intel-
lectual disability and lactic acidosis [69], and recently
with early-onset, profound sensorineural hearing loss
and leukoencephalopathy [70], making clear genotype–
phenotype correlations difficult for KARS.
Despite of many efforts it is not clear how variants
of bifunctional ARSs impact the mitochondrial func-
tion and whether or not the mitochondrial impairment
is solely recessive, similar to mutations in other
nuclear-encoded genes affecting mitochondrial transla-
tion, while neuropathy is caused by the defect of
another, probably cytosolic, function.
With the exceptions of one patient with recessive
KARS mutations developed CMT, recessive GARS or
KARS mutations are not associated with peripheral
neuropathy, rather with prominent heart and skeletal
muscle dysfunction. As the majority of patients with
recessive GARS and KARS mutations are children, it
is possible that neuropathy will develop in a later
stage; however, no reliable clinical data support this
hypothesis. There is only limited clinical information
available on parents of children with recessive disease,
who carry heterozygous GARS or KARS mutations.
In one case, the father presented with mild neuropathy
detected on electrophysiology, but the mother showed
no clinical or electrophysiological alterations [71].
These data suggest that the mechanism of disease is
different for dominant and recessive mutations. It is
possible that recessive mutations have a detrimental
effect on mitochondrial translation only in homozy-
gous state or in combination with another heterozy-
gous pathogenic mutation, leading to tissue-specific
manifestations in the heart, skeletal muscle, brain or
inner ears potentially by loss-of-function, whereas for
dominant mutations, another mechanism leads to
peripheral nerve lesion, one similar to other cytosolic
CMT-causing ARS mutations (see above) (Fig. 2,
Table 1).
Gain-of-function through neomorphic
binding
Among various ARSs, the secretion of wild-type
KARS (colon cancer cells, macrophages) and GARS
(immune cells, mouse motor neurons and differenti-
ated myotubes) to extracellular space via exosomes has
been confirmed by several studies [72,73]. Since this
observation, it has been investigated whether patho-
genic GARS mutations introduce abnormal conforma-
tional changes leading to aberrant protein interactions.
Supporting a toxic gain-of-function, recent findings in
mice carrying pathogenic Gars mutations show that
the mutant Gars protein acquires a neomorphic-bind-
ing activity that directly antagonises an essential sig-
nalling pathway for motor neuron survival [73]. CMT-
causing mutations alter the conformation of Gars,
enabling it to bind the neuropilin 1 (Nrp1) receptor.
This aberrant interaction competitively interferes with
the binding of the cognate ligand vascular endothelial
growth factor (VEGF) to Nrp1. Genetic reduction of
Nrp1 in mice worsens the neuropathy, whereas
enhanced expression of VEGF improves motor func-
tion. These findings link the selective neuronal pathol-
ogy to the neomorphic-binding activity of mutant
GARS that antagonises the VEGF–Nrp1 interaction,
and indicate that the VEGF–Nrp1 signalling axis is an
actionable target for treating CMT2D. While VEGF–
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NRP1 signalling has been implicated to play a role in
the nervous system [74] supporting its role in neuronal
migration and axonal guidance, this pathway does not
fully explain the late onset disease progression. This
pathway was also linked to developmental cardiovas-
cular defects and vascular homeostasis which was not
observed in Gars mouse models [75]. Furthermore,
abnormal interference of mutant GARS with Trk
receptors has been shown to have a role in the devel-
opment of sensory neurons [76]. Exploration of the
interacting partners of several mutant ARS variants
may shed light on a common pathological mechanism
explaining the neuromuscular phenotype.
Mitochondrial function
Several genetic forms of CMT are caused by mutations
in proteins affecting mitochondrial function such as
mitofusin 2 (MFN2), ganglioside-induced differentia-
tion-associated-protein 1 (GDAP1), heat shock protein
beta 8 (HSPB8), and heat shock protein beta 1
(HSPB1) [77], suggesting that mitochondria are impor-
tant in motor neurons. As mutations in other cytosolic
ARSs cause similar neuropathies, it is possible that
combination of several mechanisms including both
cytoplasmic and mitochondrial function might play a
role in the disease phenotype, or a so far unknown
noncanonical function specifically targeting peripheral
nerves explains why peripheral neuropathy is seen in
isolation.
Investigation of mitochondrial function of bifunc-
tional ARS has been reported in several studies. A
mitochondrial isoform of KARS have been reported
to interact with SOD1 in the mitochondria of the ner-
vous system [78], which was suggested to contribute to
mitochondrial dysfunction in ALS. More extensive
studies showed loss-of-function effect of GARS muta-
tions in Drosophila, which leads to progressive defects
of dendritic morphology due to altered mitochondrial
translation [79]. Spaulding and her colleges also found
an interesting link by identifying significantly fewer
mitochondria at nerve terminals in two different
mouse models of GARS mutations [80]. This observa-
tion highlights that mitochondrial function may be
altered in GARS mutations and a variety of mecha-
nisms may underlie the mitochondrial dysfunction,
including deficits in ATP production, failure of axonal
transport, or changes in intracellular calcium dynam-
ics. Keeping in line with this, antioxidants including
ascorbic acid and forms of glutathione were reduced in
mutant GarsNmf249/+ mice spinal cord and sciatic
nerve, suggesting changes in oxidative pathways [81].
Therefore, mitochondrial dysfunction, whether primary
or secondary, can be suggested as contributing factor
and further studies on animal models in combination
with patient-derived motor neurons are warranted.
Our preliminary data in GARS-related neuropathy
suggest that mitochondrial dysfunction involving very
specific pathways is essential for the motor nerve dys-
function (unpublished data).
Synaptic dysfunction
As neurons and muscle fibres are highly metabolically
active, it is rational to hypothesise that the neuromus-
cular junctions (NMJs) are affected by even minor
mitochondrial dysfunction. Recent data showed synap-
tic maturation abnormalities with specific, progressive
NMJ degeneration in Drosophila where ubiquitous
mutant gars was expressed [82]. In addition to this,
abnormal axonal transport was also suggested as
potential disease mechanisms, which have been
reported in a range of CMT2 models [60]. To further
strengthen this theory, both Gars mutant mouse mod-
els show muscle atrophy associated with compromised
development of the NMJ prior to synaptic degenera-
tion and highlight the neuromuscular synapse as an
important site of early, selective pathology in CMT2D
mice [83,84].
Abnormal axonal translation
The housekeeping function of the ARSs is to catalyse
the aminoacylation of tRNA with their cognate amino
acid, which is the first step of protein synthesis. Data
from in vitro aminoacylation assay and yeast comple-
mentation studies showed that some CMT mutations
do not affect the enzymatic activity, indicating that
loss of aminoacylation activity alone is not required to
cause peripheral neuropathy [85]. Furthermore, in both
CMT2D mouse models (GarsNmf249/+ and GarsC201R/
+ mice), mutations in Gars do not reduce tRNAGly
aminoacylation activity [54,83,86,87]. On the other
hand, the long axons of the peripheral nervous system
could be particularly sensitive to defective protein
translation. This idea, that mutant ARSs could affect
protein translation within the axons, was investigated
in a Drosophila model using a new method based on
noncanonical amino acid tagging, which allows to cell-
type-specifically monitor translation in vivo [88,89].
Direct evaluation of protein translation rates in sen-
sory and motor neurons expressing CMT-associated
mutant GARS (both cytoplasmic and mitochondrial
forms) and YARS showed global translational slow-
down which was not attributed to the aminoacylation
activity. It is therefore possible that defective protein
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synthesis locally in the axons act as a common patho-
genic mechanism underlying mutant tRNA synthetase-
associated CMT [89]. With the focus on bifunctional
ARSs more in-depth study required to investigate how
the mutant GARS and KARS affect cytosolic and
mitochondrial protein synthesis in isolation and how
the variants influence the interaction between two
translational systems.
Noncanonical functions of
bifunctional ARSs
It is well documented that several cytoplasmic ARSs
acquired unique signal mediators during evolution,
which facilitate numerous noncanonical biological pro-
cesses [90]. Among the various functions for ARSs
includes inflammation, transcriptional regulation, trans-
lational regulation, apoptosis, rRNA transcription,
angiogenesis, cell signalling, autoimmune response,
tRNA maturation and mitochondrial RNA splicing
[91]. Also, several cytosolic and bifunctional ARSs have
been linked to biological processes besides protein trans-
lation. Detection of GARS in the serum of normal
human subjects and mouse [72] as well as in patients
with cancer [92] indicates a role in immune defence sys-
tem, and its therapeutic potential against tumorigenesis
has been suggested [72]. Other studies showed a chaper-
one-like function for GARS whereby GARS interacts
with ubiquitin-like proteins and facilitates neddilation,
which critically regulates cell cycle progression by
degrading key regulators of the cell cycle and hence play
a crucial role in selective protein degradation [93].
The cytosolic form of KARS is part of the multi-
tRNA synthetase complex (MSC) and involved in the
housekeeping role; however, N-terminal cleavage of
KARS by caspase-8 and an interaction with syntenin
through its C-terminal end leads to dissociation from
the MSC complex and translocation to the plasma
membrane where it associates with and stabilises a 67-
kDa laminin receptor (p67LR) [94]. A study on
HCT116 colon cancer cells showed that KARS localised
to the plasma membrane is involved in cell–cell adhesion
and more importantly suppression of KARS leads to
impaired migratory abilities [95]. Migration defects in
CMT-associated mutations may be involved in periph-
eral nerve lesions. Our group identified delayed cellular
migration in patient-derived cells carrying pathogenic
dominant GARS mutations (unpublished data).
Recently, new investigations using a metabolomics
analysis in a mouse model of CMT2D, (GarsNmf249/+)
attempted to identify changes in metabolite abundance
that may be indicative of the pathophysiology [81].
Despite the fact that the metabolomics analysis of spinal
cord from a CMT2D mouse model revealed distinct
metabolite fingerprints, associated with the disease
(ascorbic acid, carnitine, glycine), none of the studied
candidates proved to be specific to the disease develop-
ment or were confirmed in CMT patient samples. Still
the potential promise of metabolite profiling to under-
stand disease mechanisms cannot be disregarded.
Conclusions and perspectives
In this review, we summarised the research on the
pathomechanisms of ARS mutations causing periph-
eral neuropathy; however, what remains particularly
unclear is the cause of the high degree of tissue speci-
ficity. Some excellent in vivo (mice, Drosophila) and
in vitro (human fibroblasts, iPSCs, neuronal cells)
model systems have been developed to study ARSs in
different tissues, which will hopefully provide further
insights into the disease mechanism. Various non-
canonical functions of ARSs have become increasingly
interesting, and by being secreted could have wide-
spread effects or could act as potential biomarkers. To
date, there is no good biomarker available to study
the progression of neuropathy in these slowly progres-
sive diseases. Understanding why peripheral nerves are
predominantly affected will open potential therapeutic
targets for a larger group of CMT patients; however,
further research is still needed.
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